Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma

By J. C. Park, Hari N Krishnakumar, S. Saladi. 2022

Subfields: Immunology, Oncology, Otorhinolaryngology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Antonia Resag
2. Luise Rupp
3. Mechthild Krause
4. Annett Linge
5. M. Schmitz
6. Ioana Plesca
7. I. Benešová
8. Rebecca Rothe

Citations in the corpus

• Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas (2026, unknown): “Although PD-L1 expression has been established as a predictive biomarker for response rates to checkpoint inhibition therapy in numerous studies [38,39], the current literature remains unclear about whether PD-L1 expression is a prognostic biomarker outside of the context of immunotherapy.”
• Type I conventional dendritic cells and CD8+ T cells predict favorable clinical outcome of head and neck squamous cell carcinoma patients (2024, background): “However, this was noticeable only in 15-30% of HNSCC patients with recurrent or metastatic disease (5, 6).”